Danka J F Stuijver1, Christof J Majoor2, Bregje van Zaane3, Patrick C Souverein4, Anthonius de Boer4, Olaf M Dekkers5, Harry R Büller6, Victor E A Gerdes3. 1. Department of Internal Medicine, Slotervaart Hospital, Amsterdam; Department of Vascular Medicine, Academic Medical Center, Amsterdam. Electronic address: danka_stuyver@hotmail.com. 2. Department of Pulmonary Medicine, Academic Medical Center, Amsterdam. 3. Department of Internal Medicine, Slotervaart Hospital, Amsterdam; Department of Vascular Medicine, Academic Medical Center, Amsterdam. 4. Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht. 5. Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands; Department of Endocrinology and Metabolism, Leiden University Medical Center, Leiden, The Netherlands. 6. Department of Vascular Medicine, Academic Medical Center, Amsterdam.
Abstract
BACKGROUND: Recently, endogenous glucocorticoid excess has been identified as a risk factor for VTE. Whether exogenous use of glucocorticoids is associated with an increased risk of VTE is unclear. We aimed to quantify the risk of symptomatic pulmonary embolism (PE) in patients using corticosteroids. METHODS: A case-control study using the PHARMO Record Linkage System, a Dutch population-based pharmacy registry, was conducted. Cases were 4,495 patients with a first hospital admission for PE between 1998 and 2008. Control subjects were 16,802 sex- and age-matched subjects without a history of PE. International Classification of Diseases codes for hospitalization were used to retrieve information on underlying conditions. RESULTS: The risk of PE was highest in the first 30 days of glucocorticoid exposure (adjusted OR, 5.9; 95% CI, 2.3-3.9) and gradually decreased with increasing duration of use (OR, 1.9; 95% CI, 1.3-2.9) for long-term users (> 1 year). Low-dose glucocorticoid use (prednisolone daily dose equivalent < 5 mg) carried a twofold increased risk of PE (OR, 1.8; 95% CI, 1.3-2.4), whereas a 10-fold increased risk was observed for the highest dose of glucocorticoids (prednisolone > 30 mg) (OR, 9.6; 95% CI, 4.3-20.5). Stratification for both duration and dose of glucocorticoid showed the highest risk of PE in recently started users compared with long-term users at the time of PE, irrespective of the dose. CONCLUSION: Patients treated with oral glucocorticoids may be at an increased risk of PE, especially during the first month of exposure. This hypothesis requires confirmation in future studies.
BACKGROUND: Recently, endogenous glucocorticoid excess has been identified as a risk factor for VTE. Whether exogenous use of glucocorticoids is associated with an increased risk of VTE is unclear. We aimed to quantify the risk of symptomatic pulmonary embolism (PE) in patients using corticosteroids. METHODS: A case-control study using the PHARMO Record Linkage System, a Dutch population-based pharmacy registry, was conducted. Cases were 4,495 patients with a first hospital admission for PE between 1998 and 2008. Control subjects were 16,802 sex- and age-matched subjects without a history of PE. International Classification of Diseases codes for hospitalization were used to retrieve information on underlying conditions. RESULTS: The risk of PE was highest in the first 30 days of glucocorticoid exposure (adjusted OR, 5.9; 95% CI, 2.3-3.9) and gradually decreased with increasing duration of use (OR, 1.9; 95% CI, 1.3-2.9) for long-term users (&gt; 1 year). Low-dose glucocorticoid use (prednisolone daily dose equivalent &lt; 5 mg) carried a twofold increased risk of PE (OR, 1.8; 95% CI, 1.3-2.4), whereas a 10-fold increased risk was observed for the highest dose of glucocorticoids (prednisolone &gt; 30 mg) (OR, 9.6; 95% CI, 4.3-20.5). Stratification for both duration and dose of glucocorticoid showed the highest risk of PE in recently started users compared with long-term users at the time of PE, irrespective of the dose. CONCLUSION:Patients treated with oral glucocorticoids may be at an increased risk of PE, especially during the first month of exposure. This hypothesis requires confirmation in future studies.
Authors: Alexis Ogdie; Neilia Kay McGill; Daniel B Shin; Junko Takeshita; Thorvardur Jon Love; Megan H Noe; Zelma C Chiesa Fuxench; Hyon K Choi; Nehal N Mehta; Joel M Gelfand Journal: Eur Heart J Date: 2018-10-14 Impact factor: 29.983
Authors: Ashwin N Ananthakrishnan; Andrew Cagan; Vivian S Gainer; Su-Chun Cheng; Tianxi Cai; Elizabeth Scoville; Gauree G Konijeti; Peter Szolovits; Stanley Y Shaw; Susanne Churchill; Elizabeth W Karlson; Shawn N Murphy; Isaac Kohane; Katherine P Liao Journal: Clin Gastroenterol Hepatol Date: 2014-03-12 Impact factor: 11.382
Authors: Ian A Buchanan; Michelle Lin; Daniel A Donoho; Arati Patel; Li Ding; Arun P Amar; Steven L Giannotta; William J Mack; Frank Attenello Journal: World Neurosurg Date: 2018-11-20 Impact factor: 2.104
Authors: Amit Tirosh; Maya Lodish; Charalampos Lyssikatos; Elena Belyavskaya; Richard A Feelders; Constantine A Stratakis Journal: Horm Metab Res Date: 2017-02-22 Impact factor: 2.936
Authors: Matthew R Boylan; Dean C Perfetti; Randa K Elmallah; Viktor E Krebs; Carl B Paulino; Michael A Mont Journal: Clin Orthop Relat Res Date: 2015-11-09 Impact factor: 4.176